RF Acquisition Corp II 
What happened
The extraordinary general meeting held on August 19 approved all six proposals related to the business combination with Nanyang Biologics. RF Acquisition Corp II filed a Form 8-K with the Securities and Exchange Commission on August 20 disclosing the vote results, which showed overwhelming shareholder support for the transaction.
The 8-K filing also revealed approximately 3.96 million share redemption requests. Against an outstanding share count of roughly 15 million, the redemption requests represent about 26% of the total base, leaving approximately 11 million shares remaining in the float. Current float data as of July 4 reflects 11,937,504 shares in the free-float pool, consistent with the redemption impact.
The deal was structured as a $1.5 billion SPAC merger combining RF Acquisition Corp II with Nanyang Biologics. Nanyang operates a platform leveraging artificial intelligence across the drug discovery pipeline, aligning with the acquirer's stated focus on technology and biotech targets in Asia. The combined company is expected to list on Nasdaq under the anticipated ticker NYB.
RFAI closed the regular session on August 20 at $12.73, up 13.7% intraday, before the after-hours explosion brought the price toward $73. The intraday gain followed weeks of quiet accumulation as the deal vote approached. The August 21 price of $66.40 reflects a market capitalization of roughly $997 million with only 366,998 shares traded in the session, underscoring the illiquid, high-beta nature of the name in its current state.
Why it matters
The redemption rate is the central variable. When SPAC shareholders redeem at high levels, the resulting float can be a fraction of the original unit count. A float compressed to roughly 11 million shares against a share count that now commands a $60-plus price creates a historically small free-float environment where even modest demand can move prices dramatically. Short interest data as of July 31 showed 1,396,000 shares sold short with just 1.0 days to cover, suggesting the conditions for a short squeeze remain present even after the redemption wave.
From a research standpoint, the deal also represents a rare pathway for a Singapore-headquartered AI biotech to access the US public markets outside of a traditional IPO. Nanyang's focus on AI-driven discovery platforms puts it at the intersection of two of the most active themes in healthcare and technology investing. If the combined entity successfully lists as NYB, institutional coverage and index inclusion could follow, expanding the investor base beyond SPAC redemption arbitrage players.
For traders, the current phase sits between deal approval and formal closing. Shares can trade in this liminal window with heavy speculative and momentum flows, but the risk of reversal is elevated once the redemption period ends and the true free-float stabilizes.
What to watch next
The formal closing and Nasdaq listing of the combined company under the NYB ticker will be the primary catalyst to monitor. Until the SEC declares the proxy/offering effective and the exchange approves the listing, RFAI shares remain in a pre-closing, pre-settlement state where pricing is largely forward-looking but subject to redemption uncertainty.
Any additional redemption filings or updated 8-K disclosures will be important. Even small increments to the redemption count can further shrink the float and sustain volatility. Investors tracking the name should watch for the final redemption tally in the closing documents, typically filed as an 8-K/A or 8-K within one to two business days after deal completion.
Finally, early trading behavior of the merged entity under NYB will test whether the post-redemption squeeze dynamics persist or normalize once the company transitions from a SPAC shell to an operating biotech. Research workflows covering AI healthcare names can use the RFAI profile page to monitor the incoming filings and event calendar as the deal progresses.